{"id":"NCT02683239","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip","officialTitle":"A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-17","primaryCompletion":"2020-12-01","completion":"2021-06-15","firstPosted":"2016-02-17","resultsPosted":"2023-10-13","lastUpdate":"2023-10-13"},"enrollment":5331,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis of the Knee or Hip"],"interventions":[{"type":"DRUG","name":"Fasinumab","otherNames":["REGN475"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fasinumab dosing regimen 1","type":"EXPERIMENTAL"},{"label":"Fasinumab dosing regimen 2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.","primaryOutcome":{"measure":"Number of Participants With Any Treatment-Emergent Adverse Event (TEAE)","timeFrame":"Baseline up to week 52","effectByArm":[{"arm":"Fasinumab-matching Placebo Q4W/Q8W","deltaMin":1055,"sd":null},{"arm":"Fasinumab 1 mg SC Q8W","deltaMin":840,"sd":null},{"arm":"Fasinumab 1 mg SC Q4W","deltaMin":885,"sd":null},{"arm":"Fasinumab 3 mg SC Q4W","deltaMin":185,"sd":null},{"arm":"Fasinumab 6 mg SC Q8W","deltaMin":1487,"sd":null},{"arm":"Fasinumab 6 mg SC Q4W","deltaMin":93,"sd":null},{"arm":"Fasinumab 9 mg SC Q4W","deltaMin":92,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":149,"countries":["United States","Bulgaria","Chile","Colombia","Denmark","Estonia","Germany","Hong Kong","Hungary","Italy","Lithuania","Mexico","Peru","Poland","Romania","Russia","South Africa","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":183,"n":1257},"commonTop":["Arthralgia","Headache","Back pain","Nasopharyngitis","Upper respiratory tract infection"]}}